Zenas BioPharma (NASDAQ:ZBIO) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Zenas BioPharma (NASDAQ:ZBIO) in a report released on Tuesday morning,Benzinga reports. They currently have a $44.00 price objective on the stock.

Several other brokerages also recently issued reports on ZBIO. Guggenheim raised their price objective on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday. Wedbush reiterated an “outperform” rating and issued a $45.00 price target on shares of Zenas BioPharma in a report on Monday, December 22nd. Wall Street Zen raised Zenas BioPharma from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Evercore started coverage on Zenas BioPharma in a report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $44.14.

Zenas BioPharma Trading Up 1.1%

Shares of ZBIO opened at $23.48 on Tuesday. The company’s fifty day simple moving average is $22.78 and its 200-day simple moving average is $27.18. The company has a market cap of $1.26 billion, a P/E ratio of -3.01 and a beta of -1.94. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.37. Zenas BioPharma has a twelve month low of $6.11 and a twelve month high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Monday, March 16th. The company reported ($4.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

Insider Buying and Selling

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. purchased 57,000 shares of Zenas BioPharma stock in a transaction on Monday, February 2nd. The stock was bought at an average cost of $17.96 per share, with a total value of $1,023,720.00. Following the transaction, the chief executive officer owned 423,155 shares of the company’s stock, valued at $7,599,863.80. This represents a 15.57% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Patricia L. Allen acquired 15,700 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were acquired at an average price of $24.85 per share, with a total value of $390,145.00. Following the completion of the purchase, the director owned 15,700 shares in the company, valued at approximately $390,145. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have acquired 202,845 shares of company stock worth $3,747,185. 16.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZBIO. Quarry LP boosted its holdings in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the last quarter. Deutsche Bank AG raised its stake in shares of Zenas BioPharma by 4.5% during the 4th quarter. Deutsche Bank AG now owns 12,781 shares of the company’s stock valued at $464,000 after buying an additional 554 shares during the last quarter. CWM LLC lifted its holdings in shares of Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after buying an additional 709 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Zenas BioPharma by 3.9% in the 3rd quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock valued at $452,000 after buying an additional 765 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Zenas BioPharma by 5.8% in the third quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after buying an additional 818 shares during the last quarter.

Key Zenas BioPharma News

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Company secured up to $250M of non-dilutive, multi‑tranche debt financing and reiterated near-term regulatory milestones (FDA filing for obexelimab expected Q2 2026; EMA H2 2026), which supports liquidity and near-term value drivers. Read More.
• Positive Sentiment: Bullish analyst activity: Citigroup cut its price target slightly (to $41) but kept a Buy rating, and HC Wainwright reaffirmed Buy with a $44 target — both signal continued upside expectations from some sell‑side desks and likely helped intraday buying. Read More.
• Positive Sentiment: Insider buying and institutional accumulation highlighted in recent data — sustained insider purchases and notable increases from institutional holders suggest conviction from insiders and some large investors. Read More.
• Neutral Sentiment: Inducement grants: the company granted 235,700 options and 33,450 RSUs to new hires to aid recruitment — supports growth plans but introduces potential future dilution as grants vest. Read More.
• Neutral Sentiment: Morgan Stanley moved its price target up to $21 but kept an Equal Weight/Hold stance — a mixed signal that marginally improves analyst outlook yet sits below the current market price. Read More.
• Negative Sentiment: Major earnings miss: Zenas reported GAAP EPS of -$4.54 vs. consensus -$1.22, a significant shortfall that raises near-term profitability and execution concerns and pressures valuation. Read More.
• Negative Sentiment: Legal risk: disclosure of an IPO‑related securities class action remains an ongoing financial and operational risk that could create litigation cost and distraction. Read More.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.